300 related articles for article (PubMed ID: 24583412)
1. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
5. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
7. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.
Ljungman P; Brand R; Hoek J; de la Camara R; Cordonnier C; Einsele H; Styczynski J; Ward KN; Cesaro S;
Clin Infect Dis; 2014 Aug; 59(4):473-81. PubMed ID: 24850801
[TBL] [Abstract][Full Text] [Related]
8. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
9. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.
Cantoni N; Hirsch HH; Khanna N; Gerull S; Buser A; Bucher C; Halter J; Heim D; Tichelli A; Gratwohl A; Stern M
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1309-14. PubMed ID: 20353832
[TBL] [Abstract][Full Text] [Related]
13. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
Nachbaur D; Clausen J; Kircher B
Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
[TBL] [Abstract][Full Text] [Related]
14. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
Schetelig J; Oswald O; Steuer N; Radonic A; Thulke S; Held TK; Oertel J; Nitsche A; Siegert W
Bone Marrow Transplant; 2003 Oct; 32(7):695-701. PubMed ID: 13130317
[TBL] [Abstract][Full Text] [Related]
16. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
[TBL] [Abstract][Full Text] [Related]
17. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
18. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
[TBL] [Abstract][Full Text] [Related]
19. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
20. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
